Marco Rossi
Magna Græcia University
81 Papers
489 Citations
Marco Rossi is an academic researcher from Magna Græcia University. The author has contributed to research in topics: Bone marrow & Multiple myeloma. The author has an hindex of 31, co-authored 77 publications. Previous affiliations of Marco Rossi include Memorial Sloan Kettering Cancer Center.
Chat about Author
Papers
Role of nucleophosmin in embryonic development and tumorigenesis.
Silvia Grisendi,Rosa Bernardi,Marco Rossi,Ke Cheng,Luipa Khandker,Katia Manova,Pier Paolo Pandolfi +6 more
TL;DR: It is demonstrated that NPM is haploinsufficient in the control of genetic stability and that Npm1 heterozygosity accelerates oncogenesis both in vitro and in vivo, and uncovered an essential developmental role for NPM.
614
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity
Marco Rossi,James W. Young +1 more
TL;DR: A review of developments in the generation of DCs from defined hemopoietic precursors in vitro has revealed the heterogeneity of these APCs and their attendant divisions of labor, and an attempt to integrate the activities of different DCs in coordinating innate and adaptive immunity is attempted.
354
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
Maria Teresa Di Martino,Emanuela Leone,Nicola Amodio,Umberto Foresta,Marta Lionetti,Maria Rita Pitari,Maria Eugenia Gallo Cantafio,Annamaria Gulla,Francesco Conforti,Eugenio Morelli,Vera Tomaino,Marco Rossi,Massimo Negrini,Manlio Ferrarini,Michele Caraglia,Masood A. Shammas,Nikhil C. Munshi,Kenneth C. Anderson,Antonino Neri,Pierosandro Tagliaferri,Pierfrancesco Tassone +20 more
TL;DR: The findings provide a proof-of-principle that formulated synthetic miR-34a has therapeutic activity in preclinical models and support a framework for development of miR -34a–based treatment strategies in MM patients.
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.
Nicola Amodio,Maria Angelica Stamato,Giada Juli,Eugenio Morelli,Mariateresa Fulciniti,Martina Manzoni,Martina Manzoni,Elisa Taiana,Elisa Taiana,Luca Agnelli,Luca Agnelli,Maria Eugenia Gallo Cantafio,Enrica Romeo,Lavinia Raimondi,Daniele Caracciolo,Valeria Zuccalà,Marco Rossi,Antonino Neri,Antonino Neri,Nikhil C. Munshi,Nikhil C. Munshi,Pierosandro Tagliaferri,Pierfrancesco Tassone,Pierfrancesco Tassone +23 more
TL;DR: A crucial role of MALAT1 in the regulation of the proteasome machinery is demonstrated, and proof-of-concept that its targeting is a novel powerful option for the treatment of MM is provided.
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth
Emanuela Leone,Eugenio Morelli,Maria Teresa Di Martino,Nicola Amodio,Umberto Foresta,Annamaria Gullà,Marco Rossi,Antonino Neri,Antonio Giordano,Nikhil C. Munshi,Kenneth C. Anderson,Pierosandro Tagliaferri,Pierfrancesco Tassone +12 more
TL;DR: The findings show the first evidence that in vivo antagonism of miR-21 exerts anti-multiple myeloma activity, providing the rationale for clinical development of mi R-21 inhibitors in this still incurable disease.
207